Scientific research company Creative Biolabs is maintaining its commitment to COVID-19 research by developing sophisticated methods for drug discovery and viral analysis. The company's research focuses on understanding viral replication mechanisms, particularly the critical role of proteolytic enzymes in SARS-CoV-2.
Researchers at Creative Biolabs are concentrating on developing inhibitors for the SARS-CoV-2 main protease, a crucial component in antiviral strategies. The company offers specialized protease detection services designed to precisely measure potential inhibitor effects, enabling scientists to identify promising candidate drugs.
The company's research encompasses multiple innovative approaches, including protease assays such as Spike-pseudovirus Based Neutralization Test, Counter Screening Test, Thermal Shift Binding Assay, and Cytotoxicity Test. These methods provide comprehensive insights into viral mechanisms and potential treatment strategies.
A key focus of Creative Biolabs' research involves SARS-CoV-2 antiviral peptides, which represent a potential alternative treatment approach. By utilizing peptide microarray analysis, researchers screen for peptides that could block virus attachment or inhibit viral multiplication.
The company's antiviral peptide discovery services include specialized techniques such as SARS-CoV-2 peptide microarray analysis, fusion peptide research, and ACE2-based peptide investigations. These services demonstrate a comprehensive approach to understanding viral interactions and potential intervention strategies.
Creative Biolabs also employs advanced cytopathic effect (CPE) detection methods, using stable virus-infected cell models and sophisticated microscopic imaging techniques. This approach allows for precise evaluation of viral replication and the potential effectiveness of antiviral inhibitors.
With extensive experience in antiviral drug research and development, Creative Biolabs continues to contribute to the global scientific effort to understand and combat SARS-CoV-2. The company's high-tech experimental platform and specialized expertise position it as a significant contributor to ongoing COVID-19 research initiatives.
